Advertisement
Donna L. LaVoie, President & CEO, commented, "With personalized medicinetop of mind across a number of different constituencies, Interleukin Geneticsis well positioned to capitalize on its strengths in genetics research todevelop a series of innovative preventive products. LaVoie Group looksforward to continue helping Interleukin communicate its story."
Advertisement
About Interleukin
Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalizedhealth company that develops preventive consumer products and genetic testsfor sale to the emerging personalized health market. Focused on the future ofhealth and medicine, Interleukin uses its leading genetics research andscientific capabilities to develop and test innovative preventive andtherapeutic products. Interleukin currently offers an array of Nutraceuticalsand OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which aresold at the nation's largest food, drug and mass retailers, and hascommercialized genetic tests for periodontal disease risk assessment,cardiovascular risk assessment, and general nutrition assessment. Interleukinis headquartered in Waltham, MA. For more information about Interleukin andits ongoing programs, please visit www.ilgenetics.com.
About LaVoie Group
LaVoie Group provides senior level strategic counsel and tacticalimplementation of public, investor and corporate communications programsdesigned to properly position create visibility and drive value for eachclient. Our clients range from private start-ups to industry leaders in lifesciences. For more information, please visit www.lavoiegroup.com.
SOURCE LaVoie Group
